Puretech Health - PRTC STOCK NEWS

PureTech's Founded Entity, Vedanta Biosciences, published additional Phase 2 results for VE303, their lead candidate for preventing recurrent Clostridioides difficile infection (rCDI), in Nature Medicine. The study showed VE303, a first-in-class Live Biotherapeutic Product consisting of eight bacterial strains, was well-tolerated and reduced CDI recurrence odds by over 80% compared to placebo.

The new analyses revealed that VE303 works through multiple mechanisms, including restoring healthy gut microbial community, decreasing inflammation, and increasing protective metabolites. The research identified predictors of VE303 colonization and clinical response, showing that strain abundance was predictive of remaining recurrence-free.

These findings informed the design of the ongoing global Phase 3 RESTORATiVE303 study, with topline data expected in 2026.

PureTech Health (PRTC) announced that the FDA has granted Fast Track designation to LYT-200, their first-in-class anti-galectin-9 monoclonal antibody, for treating acute myeloid leukemia (AML). This follows previous FDA recognitions including Orphan Drug designation for AML and Fast Track designation for head and neck cancers.

LYT-200 is currently being evaluated in two Phase 1/2 clinical trials: one for hematological malignancies (AML and high-risk myelodysplastic syndrome) and another for advanced/metastatic solid tumors. The drug has shown favorable safety profiles in both trials, with early signals of clinical activity both as a monotherapy and in combination with other treatments.

The treatment works by directly killing cancer cells through apoptosis and DNA damage while reactivating the immune system's anti-cancer mechanisms. PureTech plans to advance LYT-200 through its Founded Entity, Gallop Oncology.

PureTech Health (Nasdaq: PRTC, LSE: PRTC), a clinical-stage biotherapeutics company focused on developing treatments for devastating diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. CEO Bharatt Chowrira will deliver a presentation on Wednesday, January 15, 2025, at 11:15am PST / 2:15pm EST. The presentation will be accessible to investors and interested parties through a webcast available on the company's investor relations website.

PureTech Health (Nasdaq: PRTC, LSE: PRTC) has announced the appointment of UBS as its UK Corporate Broker. The company, which is dual-listed on Nasdaq and London Stock Exchange, made this strategic move to enhance its corporate brokerage services in the United Kingdom.

PureTech Health announced positive results from the ELEVATE IPF Phase 2b trial evaluating deupirfenidone for idiopathic pulmonary fibrosis (IPF). The trial achieved its primary and key secondary endpoints with a 98.5% probability of superiority over placebo in slowing lung function decline.

The higher dose of deupirfenidone (825 mg TID) showed an 80.9% treatment effect versus placebo (-21.5 mL vs. -112.5 mL decline), significantly outperforming pirfenidone's 54.1% effect (-51.6 mL vs. -112.5 mL). Both doses demonstrated favorable tolerability with comparable gastrointestinal adverse events to pirfenidone.

Over 90% of trial completers opted to enroll in the ongoing open-label extension study, with the longest treatment duration reaching 79-81 weeks.

Seaport Therapeutics, a PureTech Founded Entity, presented additional data from its Phase 1 study of SPT-300 at the ACNP Annual Meeting 2024. The study, involving 99 participants, evaluated an oral prodrug of allopregnanolone designed for treating major depressive disorder. Key findings showed SPT-300 was well-tolerated with mild to moderate adverse effects, achieving blood levels up to nine times greater than unmodified allopregnanolone. The drug demonstrated pharmacodynamic activity through EEG and VOG assessments, with effects peaking at 4 hours post-dose and diminishing within 6-8 hours. Based on these results, SPT-300 is deemed suitable for chronic, nightly dosing in a planned Phase 2b placebo-controlled study.

PureTech Health presented data from its Phase 1b trial of LYT-200, a first-in-class anti-galectin-9 monoclonal antibody, for treating relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) at the 2024 ASH Annual Meeting.

The trial evaluated LYT-200 both as monotherapy and in combination with venetoclax and hypomethylating agents. In monotherapy, 59% of 22 evaluable patients achieved stable disease or better, with two partial responses. In combination therapy, 80% of 15 evaluable patients achieved stable disease or better, including two complete responses.

The treatment showed a favorable safety profile across all dose levels with no dose-limiting toxicities. The mean duration of treatment exceeded two months in both arms, surpassing the standard survival rate for venetoclax/HMA-refractory patients.

PureTech Health (Nasdaq: PRTC) announced that its Founded Entity, Seaport Therapeutics, has appointed Sandi Peterson to its Board of Directors. Peterson, currently Lead Independent Director at Microsoft and Operating Partner at Clayton, Dubilier & Rice, brings significant experience from her previous role as Group Worldwide Chair at Johnson & Johnson. Her appointment strengthens Seaport's leadership as the company advances its development of novel neuropsychiatric medicines. Peterson's extensive background includes executive positions at Bayer, Medco Health Solutions, and Nabisco, with recognition from Fortune Magazine's Most Powerful Women in Business list.

PureTech Health (Nasdaq: PRTC, LSE: PRTC), a clinical-stage biotherapeutics company, has announced its management team's participation in two upcoming investor conferences. Bharatt Chowrira, CEO, and Eric Elenko, Co-founder and President, will present at the UBS Global Healthcare Conference on November 13, 2024, at 8:45 a.m. PST, and the Jefferies London Healthcare Conference on November 19, 2024, at 2:30 p.m. GMT. Webcasts of both presentations will be accessible through PureTech's investor relations website.